DexCom, Inc. (NASDAQ:DXCM) Shares Sold by M&T Bank Corp

M&T Bank Corp decreased its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 9.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 34,369 shares of the medical device company's stock after selling 3,411 shares during the period. M&T Bank Corp's holdings in DexCom were worth $2,347,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of DXCM. Golden State Wealth Management LLC grew its stake in shares of DexCom by 211.2% in the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after buying an additional 264 shares during the period. Optiver Holding B.V. purchased a new stake in shares of DexCom in the 4th quarter valued at approximately $33,000. TD Private Client Wealth LLC grew its stake in shares of DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after buying an additional 167 shares during the period. Larson Financial Group LLC grew its stake in shares of DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after buying an additional 137 shares during the period. Finally, Heck Capital Advisors LLC purchased a new stake in shares of DexCom in the 4th quarter valued at approximately $38,000. Institutional investors and hedge funds own 97.75% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on DXCM. Wall Street Zen cut shares of DexCom from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Barclays increased their price target on shares of DexCom from $90.00 to $93.00 and gave the company an "equal weight" rating in a research note on Monday, May 5th. The Goldman Sachs Group started coverage on shares of DexCom in a research report on Friday, May 30th. They set a "buy" rating and a $104.00 price objective for the company. Cfra Research raised shares of DexCom to a "hold" rating in a research report on Friday, March 21st. Finally, Truist Financial started coverage on shares of DexCom in a research report on Monday, June 16th. They set a "buy" rating and a $102.00 price objective for the company. Five research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, DexCom currently has a consensus rating of "Moderate Buy" and an average target price of $98.50.

Insider Activity

In other news, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction on Monday, June 16th. The shares were sold at an average price of $83.13, for a total transaction of $228,607.50. Following the completion of the sale, the director directly owned 56,621 shares of the company's stock, valued at approximately $4,706,903.73. The trade was a 4.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Sadie Stern sold 1,466 shares of DexCom stock in a transaction on Thursday, June 26th. The stock was sold at an average price of $85.06, for a total transaction of $124,697.96. Following the sale, the executive vice president directly owned 108,155 shares of the company's stock, valued at approximately $9,199,664.30. This trade represents a 1.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 27,190 shares of company stock valued at $2,281,732 in the last 90 days. Company insiders own 0.32% of the company's stock.

DexCom Stock Performance

Shares of DXCM stock opened at $83.37 on Friday. The company has a quick ratio of 1.32, a current ratio of 1.50 and a debt-to-equity ratio of 0.55. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $117.19. The stock has a market capitalization of $32.69 billion, a PE ratio of 62.22, a P/E/G ratio of 1.82 and a beta of 1.44. The firm has a 50 day moving average of $84.35 and a two-hundred day moving average of $80.00.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The business had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. During the same period in the prior year, the business earned $0.32 EPS. The business's quarterly revenue was up 12.5% on a year-over-year basis. On average, research analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.